

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5795851

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	INTERFACE BIOLOGICS, INC.	07/30/2019
RECEIVING PARTY DATA		
Name:	EVONIK CANADA INC.	
Street Address:	3380 SOUTH SERVICE ROAD	
City:	BURLINGTON	
State/Country:	CANADA	
Postal Code:	ON L7N3J5	
PROPERTY NUMBERS Total: 1		
	Property Type	Number
	Application Number:	16386409
CORRESPONDENCE DATA		
Fax Number:	(973)929-8839	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	9739298833	
Email:	ipm-na@evonik.com	
Correspondent Name:	EVONIK CORPORATION	
Address Line 1:	299 JEFFERSON ROAD	
Address Line 4:	PARSIPPANY, NEW JERSEY 07054	
ATTORNEY DOCKET NUMBER:	2016P21002WOUS	
NAME OF SUBMITTER:	LINDA S. LI	
SIGNATURE:	/Linda S. Li/	
DATE SIGNED:	10/30/2019	
Total Attachments: 6		
source=Patent_Assignment_Executed#page1.tif		
source=Patent_Assignment_Executed#page2.tif		
source=Patent_Assignment_Executed#page3.tif		
source=Patent_Assignment_Executed#page4.tif		
source=Patent_Assignment_Executed#page5.tif		
source=Patent_Assignment_Executed#page6.tif		

PATENT ASSIGNMENT

THIS PATENT ASSIGNMENT ("**Assignment**") is made and entered into as of this 30th day of July, 2019 ("**Effective Date**"), by and between Interface Biologics, Inc., an Ontario corporation having an address at MaRS Centre, South Tower, 101 College Street, Suite 300, Toronto, Ontario, M5G 1L7 ("**Assignor**") and Evonik Canada Inc., an Alberta corporation having an address at 3380 South Service Rd., Burlington, Ontario, L7N 3J5 ("**Assignee**").

WHEREAS, Assignor and Assignee, are parties to that certain Asset Purchase and License Agreement dated as of July 30, 2019 (the "**Agreement**"); and

WHEREAS, pursuant to the Agreement, Assignor wishes to assign to Assignee, and Assignee wishes to acquire from Assignor, all patents, patent applications, registered designs, and registered design applications that constitute Acquired Patents (as that term is defined in the Agreement), any continuations, divisions, continuations-in-part, reissues, re-examinations, extensions or foreign equivalents thereof, and the subject matter of all claims recited therein, including but not limited to the patents, patent applications, registered designs and registered design applications set forth on Schedule A attached hereto (collectively, the "**Patents**").

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Assignor does hereby sell, assign, transfer and set over to Assignee, its entire right, title and interest in and to the Patents, for Canada, the United States and for all other countries, including, without limitation, all corresponding rights that are or may be secured under the laws of Canada, the United States or any other country or under international conventions and treaties, now or hereafter in effect, for Assignee's own use and enjoyment, and for the use and enjoyment of Assignee's successors, assigns or other legal representatives, as fully and entirely as the same would have been held and enjoyed by Assignor if this Assignment had not been made, together with all income, royalties or payments due or payable with respect thereto as of the Effective Date or thereafter, all causes of action (either in law or in equity) relating thereto, and the right to sue, counterclaim, and recover damages for past, present or future infringement or other unauthorized use of the Patents.

Assignor hereby requests the Commissioner of Patents, and the corresponding entities or agencies in any other applicable countries, to record Assignee as the assignee and owner of the Patents.

To the extent that any provision of this Assignment conflicts or is inconsistent with the terms of the Agreement, the Agreement will govern.

This Assignment and any dispute arising out of or relating to or in connection with this Assignment shall be governed by, and construed in accordance with, the laws of the Province of Ontario and the Federal laws of Canada applicable therein, regardless of the laws that might otherwise govern under applicable principles of conflicts of laws thereof.

This Assignment may be executed in one or more counterparts, and by each of the parties in separate counterparts, each of which when executed shall be deemed to be an original but all of which taken together shall constitute one and the same original instrument.


Delivery of an executed counterpart of a signature page to this Assignment by electronic means (including portable document format) shall be as effective as delivery of a manually executed counterpart of this Assignment.


* * * * *

[The remainder of this page is intentionally left blank]

IN WITNESS WHEREOF, Assignor and Assignee have caused this Assignment to be executed by their duly authorized representatives as of the Effective Date.

INTERFACE BIOLOGICS, INC.

Per: 
Name: THOMAS P. NOVOS
Title: President & CEO

Witness: 
Name: Kelley Dealnoy

EVONIK CANADA INC.

Per: _____
Name: _____
Title: _____

Witness: _____
Name: _____

Per: _____
Name: _____
Title: _____

Witness: _____
Name: _____

(Signature Page for Patent Assignment)


IN WITNESS WHEREOF, Assignor and Assignee have caused this Assignment to be executed by their duly authorized representatives as of the Effective Date.


INTERFACE BIOLOGICS, INC.

Per: _____
Name: _____
Title: _____

Witness: _____
Name: _____

EVONIK CANADA INC.

Per:  _____
Name: Dr. Jean-Luc Herbeaux
Title: Head Business Line Health Care

Witness:  _____
Name: Joanne Booge

Per: _____
Name: _____
Title: _____

Witness: _____
Name: _____

(Signature Page for Patent Assignment)

IN WITNESS WHEREOF, Assignor and Assignee have caused this Assignment to be executed by their duly authorized representatives as of the Effective Date.

INTERFACE BIOLOGICS, INC.


Per: _____
Name: _____
Title: _____


Witness: _____
Name: _____

EVONIK CANADA INC.

Per: _____
Name: _____
Title: _____

Witness: _____
Name: _____

Per: 
Name: KEVIN W BURTON
Title: HEAD, GLOBAL HEALTHCARE SOLUTIONS

Witness: 
Name: Sheila Burton

(Signature Page for Patent Assignment)

SCHEDULE A

Patents

Title	Serial No./Patent No.	Status
SURFACE MODIFYING MACROMOLECULES WITH HIGH DEGRADATION TEMPERATURES AND USES THEREOF	U.S.S.N. 12/002,226 Patent No. 8,071,683	Granted
	U.S.S.N. 13/185,985 Patent No. 8,178,620	Granted
	U.S.S.N. 13/465,406 Patent No. 8,338,537	Granted
	Canada Patent No. 2,672,593	Granted
	European Patent No. 2102258	Granted
	Japan Patent No. 5491191	Granted
SURFACE MODIFYING MACROMOLECULES WITH HIGH DEGRADATION TEMPERATURES AND USES THEREOF	U.S.S.N. 13/323,427 Patent No. 8,318,867	Granted
	U.S.S.N. 14/188,441 Patent No. 9,751,972	Granted
	U.S.S.N. 15/665,528	Pending
	Canada Pat. No. 2,735,442	Granted
	China Patent No. ZL 200980142812.7	Granted
	European Appl. No. 09810679.2	Pending
	Hong Kong Patent No. 1162556	Granted
	Japan Patent No. 5529135	Granted
THERMOPLASTIC POLYURETHANE ADMIXTURES ¹	U.S.S.N. 14/210,687 Patent No. 9,206,283	Granted
	U.S.S.N. 14/947,026 Patent No. 9,744,269	Granted
CATHETERS WITH HIGH-PURITY FLUOROPOLYMER ADDITIVES ¹	U.S.S.N. 13/950,592 Patent No. 8,603,070	Granted
	U.S.S.N. 14/100,671 Patent No. 8,876,797	Granted
	U.S.S.N. 14/519,589 Patent No. 9,731,049	Granted
	U.S.S.N. 15/132,116 Patent No. 9,867,908	Granted
DIALYSIS CATHETERS WITH FLUOROPOLYMER ADDITIVES ¹	U.S.S.N. 13/950,585 Patent No. 8,784,402	Granted
CATHETER SHAFT WITH ENHANCED PLATELET ANTI-ADHESION SURFACES ¹	U.S.S.N. 14/215,145 Patent No. 9,789,229	Granted
MEDICAL DEVICES HAVING SURFACE MODIFIERS ¹	U.S.S.N. 15/991,961	Pending
IMPLANTABLE GLUCOSE SENSORS HAVING A BIOSTABLE SURFACE	U.S.S.N. 16/300,404	Pending
	European Appl. No. 17795688.5	Pending
CARBONATE-LINKED SURFACE MODIFYING MACROMOLECULES	PCT Appl. No. PCT/CA2019/050281	Pending
SURFACES RESISTANT TO BACTERIAL ADHESION	PCT Appl. No. PCT/CA2019/050683	Pending
PACKAGING MATERIALS INCLUDING A BARRIER FILM	U.S.S.N. 14/875,818 Patent No. 9,764,884	Granted
PROSTHETIC VALVES HAVING A MODIFIED SURFACE	PCT Appl. No. PCT/CA2018/050629	Pending
VASCULAR GRAFTS HAVING A MODIFIED SURFACE	PCT Appl. No. PCT/CA2018/050628	Pending
OLIGOFLUORINATED CROSS-LINKED POLYMERS AND USES THEREOF	U.S.S.N. 15/373,138 Patent No. 10,039,864	Granted
	Canada Patent No. 2,701,186	Granted
	European Patent No. 2203498	Granted
PLASTICIZED PVC ADMIXTURES WITH SURFACE MODIFYING MACROMOLECULES AND ARTICLES	U.S.S.N. 16/386,409	Pending
	Brazil Appl. No. BR112019007896- 7	Pending

MADE THEREFROM ²	Canada Appl. No. CA3041063	Pending
	China Appl. No. CN201780078034.4	Pending
	Europe Appl. No. EP17862608.1	Pending
	Japan Appl. No. TBD ²	Pending
	Mexico Appl. No. MX/a/2019/004419	Pending

¹ Joint filings with AngioDynamics and considered Joint IP as defined in and pursuant to the terms of the AngioDynamics Contract

² National phase filings in progress